The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib + best supportive care (BSC) compared with placebo + BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial.
 
Sebastian Stintzing
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb GmbH; Merck KGaA; MSD; Nordic Bioscience; Pfizer; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Merck KGaA; MSD; Nordic Bioscience; Pierre Fabre; Roche; Seagen; SERVIER; TERUMO
Research Funding - Amgen (Inst); Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Elevar Therapeutics (Inst); Elevation Oncology; GlaxoSmithKline; Gritstone Bio (Inst); Hookipa Biotech; IgM Biosciences (I); Janssen Oncology; Merck (Inst); Merck Serono; natera; Pfizer; Pfizer (Inst); Seagen; Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Novartis; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda (I)
Consulting or Advisory Role - HMP
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pfizer; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Alberto F. Sobrero
Consulting or Advisory Role - Amgen; Bayer; BMS; Celgene; GlaxoSmithKline; Hutchmed; Menarini; Merck Serono; MSD Oncology; Roche; Sanofi; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Roche
 
James C. Yao
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Chiasma; Crinetics Pharmaceuticals; Hutchison MediPharma; Ipsen
Research Funding - Advanced Accelerator Applications; Novartis
 
Stefan Kasper
Employment - University Hospital Essen (I)
Honoraria - Amgen; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Incyte; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; BMS; Lilly; Merck Serono; Pierre Fabre; Roche; Sanofi
Other Relationship - Amgen; Bristol-Myers Squibb; Lilly; Merck Serono; Roche; Sanofi
 
Dirk Arnold
Honoraria - Amgen; Art Tempi; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Medscape; PriME Oncology; Roche; Sanofi; Servier; Sirtex Medical; Terumo; TRM Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Lilly; Merck Serono; Merck Sharp & Dohme; Oncolytics; Roche; Sanofi; Sanofi; Servier; Sirtex Medical; Terumo
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - ESMO; European Organisation for Research and Treatment of Cancer (EORTC); German Cancer Society
 
Edin Basic
Employment - Takeda
 
Matthias Granold
Employment - Takeda
 
Marco Petschulies
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Liwen Wu
Employment - Takeda
 
Lucy Chen
Employment - Takeda
 
Zhao Yang
Employment - HUTCHMED
Stock and Other Ownership Interests - HUTCHMED
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)